The impact of obesity on bone health: molecular pathways, metabolic interactions, and associated pathologies
September 19, 2025 / Obesity / Bone Health / NAFLD / Osteoporosis / Inflammation
Obesity and NAFLD disrupt bone metabolism via chronic inflammation, hormonal imbalances, and gut microbiota changes, increasing risks for osteopenia and osteoporosis—particularly in youth and postmenopausal women—highlighting the need for targeted prevention strategies.
New obesity drug RES-010 targets metabolism to prevent weight regain
September 19, 2025 / Obesity Treatment / Metabolic Reprogramming / RNA Therapy / Weight Regain / RES-010
RES-010 is a novel antisense RNA therapy targeting miR-22 to reprogram metabolism, not suppress appetite—promoting durable fat loss, preserving lean mass, and preventing weight regain. Early pre-clinical results are promising; Phase 1 human trials are underway.
Scientists unveil new obesity drug that reprograms fat and energy use
September 18, 2025 / Obesity Drug / Metabolic Health / RNA Therapy / Weight Loss / RES-010
RES-010, a novel antisense oligonucleotide targeting miR-22, reprograms fat metabolism and mitochondrial function to induce sustained weight loss without rebound. Pre-clinical studies show significant fat loss, and a Phase 1 human trial is underway.
Oral GLP-1 Drug Orforglipron Promotes Substantial Weight Loss in Clinical Trial
September 18, 2025 / Orforglipron / Oral GLP-1 / Obesity Treatment / Weight Loss / Cardiometabolic Health
Orforglipron, an oral GLP-1 receptor agonist, led to significant weight loss and improved cardiometabolic risk factors in a Phase 3 trial, offering a promising non-injectable alternative for obesity treatment with global scalability advantages.
The future of obesity management—quintuple and other super polyagonists for weight loss and maintenance?
September 22, 2024 / Quintuple Agonist / Obesity Treatment / GLP-1 GIP PPAR / Metabolic Health / Weight Loss
A novel quintuple agonist combining GLP-1, GIP, and pan-PPAR activation shows promise in preclinical studies for enhancing weight loss, insulin sensitivity, and lipid regulation—potentially redefining future obesity and metabolic disorder treatments.
Weight-loss surgery outperforms GLP-1 drugs for diabetes and obesity, study finds
September 19, 2025 / Weight-Loss Surgery / Type 2 Diabetes / GLP-1 Drugs / Obesity Treatment / Metabolic Health
In a 10-year study, metabolic surgery outperformed GLP-1 drugs in improving survival, cardiac health, and diabetes outcomes in patients with type 2 diabetes and obesity, reaffirming surgery’s long-term superiority over pharmacologic treatment.
Weight-Loss Surgery Outperforms GLP-1 Drugs, Study Argues
September 19, 2025 / Weight-Loss Surgery / GLP-1 Drugs / Type 2 Diabetes / Obesity Treatment / Long-Term Outcomes
A Cleveland Clinic study found weight-loss surgery yields greater long-term benefits than GLP-1 drugs, including lower risks of death, heart and kidney disease, and diabetes complications, while also delivering superior weight loss and metabolic control in type 2 diabetes patients.
Pfizer’s $4.9B Metsera Acquisition Positions It to Become Major Player in Obesity Drugs & More
September 22, 2025 / Pfizer Acquisition / Obesity Drugs / GLP-1 Therapy / Metabolic Medicines / Amylin Receptor
Pfizer’s $4.9B acquisition of Metsera advances its position in obesity treatment, gaining next-gen GLP-1 and amylin-based therapies with potential for monthly or quarterly dosing—aiming to improve efficacy, patient adherence, and supply chain efficiency in metabolic disease management.
Keto may aid weight loss but lead to high cholesterol, mouse study suggests
September 20, 2025 / Keto Diet / Weight Loss / Metabolic Health / Fatty Liver / Glucose Regulation
A long-term mouse study shows ketogenic diets can promote weight loss but may impair glucose regulation, elevate blood lipids, and cause fatty liver—raising concerns about prolonged keto use for obesity or diabetes management without further human studies.
Researchers provide new insights into how exercise helps lose weight
September 16, 2024 / Exercise Metabolism / Lac-Phe Molecule / Appetite Suppression / Weight Loss Mechanism / Brain Neurons
Researchers discovered that Lac-Phe, a molecule produced during intense exercise, suppresses appetite by inhibiting hunger-promoting AgRP neurons and activating PVH neurons in the brain—revealing a promising new mechanism for weight loss without adverse behavioral effects.
Bariatric surgery for weight loss shows greater long-term benefits than GLP-1 medicines
September 16, 2025 / Bariatric Surgery / Type 2 Diabetes / GLP-1 Drugs / Weight Loss Outcomes / Metabolic Health
A 10-year Cleveland Clinic study found bariatric surgery provides greater long-term benefits than GLP-1 drugs for people with obesity and type 2 diabetes, including superior weight loss, metabolic control, and reduced risks of death, heart, kidney, and eye disease.
Dan Marino’s metabolic liver disease highlights growing health concern
September 21, 2025 / Dan Marino / MASH Diagnosis / Liver Disease / Metabolic Health / Obesity-Related Conditions
Dan Marino’s MASH diagnosis highlights a growing public health concern—this silent liver disease, driven by obesity, type 2 diabetes, and metabolic syndrome, causes inflammation and liver damage and often goes undetected until advanced stages.
New drug could be first to stop deadly fatty liver disease
September 17, 2025 / MASH Treatment / Fatty Liver Disease / DGAT2 Inhibitor / ION224 Drug / Liver Inflammation
UC San Diego researchers found that ION224, a DGAT2 inhibitor, significantly reduces liver fat and inflammation in MASH patients. This first-in-class drug shows promise in halting disease progression without serious side effects, offering hope for targeted treatment.
Roche’s Metabolic Drug Strategy Extends to the Liver Disease MASH With $2.4B 89bio Acquisition
September 18, 2025 / Roche Acquisition / MASH Treatment / Pegozafermin Drug / Fatty Liver Disease / FGF21 Analog
Roche is acquiring 89bio for $2.4B to obtain pegozafermin, a long-acting FGF21 analog in Phase 3 trials for MASH. The drug targets liver inflammation and fibrosis, offering a potential new treatment for moderate to severe fatty liver disease.
Roche pays $3.5bn for 89bio and its potential best-in-disease treatment MASH drug
September 18, 2025 / Roche Acquisition / MASH Treatment / Pegozafermin Drug / FGF21 Analog / Liver Fibrosis
Roche is acquiring 89bio for up to $3.5B to gain pegozafermin, a long-acting FGF21 analog in Phase III trials for MASH. The drug targets liver fibrosis and inflammation, offering promise for moderate to severe stages of the disease.
Roche Makes Major MASH Move With $3.5B 89bio Buy
September 18, 2025 / Roche Acquisition / Pegozafermin Drug / MASH Treatment / FGF21 Analog / Liver Fibrosis
Roche is acquiring 89bio for up to $3.5B to gain pegozafermin, a late-stage FGF21 analog for MASH. Phase IIb results show significant improvements in liver fibrosis and MASH resolution, positioning Roche to compete in this expanding treatment market.
Metabolic syndrome linked to increased risk of Parkinson’s disease
September 19, 2025 / Metabolic Syndrome / Parkinson’s Disease / Neurodegenerative Risk / UK Biobank Study / Metabolic Health
A large UK Biobank study found that individuals with metabolic syndrome have a significantly increased risk of developing Parkinson’s disease, with risk rising proportionally to the number of metabolic factors—highlighting a potential link between metabolic health and neurodegeneration.
Metabolic Issues More Common in Patients With HIV
September 18, 2025 / HIV Patients / Metabolic Syndrome / MASLD Risk / Antiretroviral Therapy / Liver Health
People living with HIV on antiretroviral therapy show higher rates of dyslipidemia and MASLD markers, but not enough to classify them as more metabolically ill than the general population—highlighting the need for larger, more definitive studies.
Higher arsenic exposure linked to increased risk of metabolic liver disease
September 22, 2025 / Arsenic Exposure / MASLD Risk / Liver Disease / Environmental Toxins / Public Health
A U.S. population-based study found higher urinary arsenic levels significantly increased the odds of MASLD by up to 55%, independent of traditional risk factors—suggesting environmental arsenic exposure may play a key role in liver disease development.